{"name":"Suzhou Junde Biotechnology Co., Ltd","slug":"suzhou-junde-biotechnology-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxOSkJVaXVScmZMeUthSF9SeUw3T0Y4MHZsWTd2dmhXYVpWZmlVdkZYdzhDYlAySGlpX0s4dzUxc0FyckhCM0liZVB0NHVJU0hWZmx5ckdQRVdId0JIWDd6WmNOTndBRW5DcVRReTVuc2o0MlY4UXlvcE50dnhWY3RMV2ZfUnc5RlA0R0NTNEcyNldNSGtMZGFEd0FRQmZyQlE0OERj?oc=5","date":"2025-07-22","type":"pipeline","source":"BioWorld News","summary":"34 mainland China biotechs file for Hong Kong IPO in H1 2025 - BioWorld News","headline":"34 mainland China biotechs file for Hong Kong IPO in H1 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AJBVV95cUxPN202TUJ4Nm1xZ3AwUEFZbjh0cGl1NWc5WDJFLW03VHhlZnV0R28wOFR4UC0wNlJnSHV6WVY4aG9mdEtDZ1phbHdKWnUyaEhuTzUteERfdkpJdnA1S1VZVGp3TlpwcXhxeEJZeEttTzYwZlNKTHBtZ0dXVGhtSnZZeUs3bkxhTFpVZ2d0c3d5Mm83eGtlRmZJU3FseW5lYVhoeVBESV8zRW9fb1FPTk1jd1ZUb1dyeGlrTFBuMUhCcFBzTnI2azJadG9fWHlxVS1RX0Roc3NNbnIwS19aVEJXbE5zQUJBUHVwdDhhYlluVGZhcXlRVW1wak5xazJ2bFlNMmFzaV9oVENvOWRsTEJFdVRwc2Z3TURveTlIRkJRQXpLV3JWTldMRnBwZG1EdEJSVGdTVlhUVktvS3drSHFrTGFZUmhpcnpOUXl2cEN5OERFZVpE?oc=5","date":"2025-06-17","type":"trial","source":"GlobeNewswire","summary":"Oligonucleotides Clinical Trial Pipeline Analysis - GlobeNewswire","headline":"Oligonucleotides Clinical Trial Pipeline Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgJBVV95cUxQWUZ5cHh6eEdSQTd1Y2RQUlVMRnE0MFR4TG5ZbVVrOV84WHBqaDJTM0JhMkhBblFRdHlMUDVZVmZXeTZoX1NBaE1TM25ldm1pMWhndVkwM0hKTk1kNGFpemxTX01YeVVPMzV0d3BwdTJlX0tFWThzdFR6SGZ6ODJsRWl2Y0xldWd3Z095ZGVFU0xOZWhCR3JfWld4YlRyWWFxZFlHcjBVQ1I0cTBKWEY5c2N5YUlRZGswYmRKZ1VlYUpybkFTX3Y4UzU5UkxHX0cwbmd0Y3Vqak9UUzFITVh1djdIbUxMbUh3Tjl0WDJ6bGUxRDVwSFppRTdmNmNYal9mUVpxb1NzTWFDLVRhV3VqZ2luRjdaOGtpaXc?oc=5","date":"2025-06-03","type":"deal","source":"GlobeNewswire","summary":"Transpire Bio Enters into Exclusive License Agreement with - GlobeNewswire","headline":"Transpire Bio Enters into Exclusive License Agreement with","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AJBVV95cUxQcjFaR0ttSWtmdXVpZmE0VUhJMkFFZXNKRWV6MnBhbl9WNWUtUVBLS1BKWkdoQTQxUHBfZEdOeWYxMmV4M0RySEJJa3NvelQ3SkN4UHg1eTZBNy1WR3RKMGlmSmh6SDRnU21PVTJGOFBSOUIwU09xUXNVRmhpdzgzXzhLUjN5RmlDOGRXejZKMFJhNXpHdkNrVV9rRUFRV3N4bXVWd3lzNExUR1JBckFOeUxGSk9sb0dCU1pfRGlDcFVmcnV3QXJ1Yl9XMGxKYXQ5VGFkV2hLcmRvQXNGbXRKbERRNDRDZ0JKVTBaSU5pQTRSOG40M1FuQmZhNFFuU2xPNWJ4dFp3RlBCWFMtek1PVU1ydElMbHhPV2MwRzBRVU1RWHcxN1RYRWhmREVKaU5yZFVrcThOb3pwU0Z2YnVkbTViXzJXZmRVLVA5TWc4aldWbXBEdlNsTTUtQk92NnVDNzFZaUVJU2t4QnNM?oc=5","date":"2023-06-05","type":"trial","source":"GlobeNewswire","summary":"Shanghai Escugen Biotechnology Co., Ltd., a partner of Levena Biopharma, a Sorrento Company, releases positive results from a first-in-human study of ESG401, a TROP2 Antibody Drug Conjugate in patient","headline":"Shanghai Escugen Biotechnology Co., Ltd., a partner of Levena Biopharma, a Sorrento Company, releases positive results f","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiqwJBVV95cUxNOTRwNkJCQWJJZkp5eGVSZzJtakZsbTVNMnlOcUFkZVpsakZINlNEbFV2XzctOFp6MFh1T0VsNTBQUUo2SzN0Q3k2by0tRndWZDRwbDBleVFpRWx5WEpkNXYxQlFwTXJvdVZhaXRlZko0VGZnaTFvYXcyZzZxb3E1MUx4MXl2ZlNWZjNKQm0wbjRBZ3hfWGRKVXZmTHpZZVF5YXFDSGdaSFNkdXFHQ2E2X3pMZmhydEFrZGRSQXlfRGJOMWZoODlJbjVXVW9QbFJuUEc0cldSR2ViY0tEa2hrbGhHYVFlMHctZWY4UDBGTE1fOUhvVkNRRkVsUVNpcmZwY0lXUEtfRzRtSVExZ05ZZWtUYnE0Mm10TFU4aUN4X0NPQS1hdGV4b0VvRQ?oc=5","date":"2023-05-09","type":"pipeline","source":"businesswire.com","summary":"Zion Pharma Announces Global Agreement with Roche to Develop and Commercialize a Blood Brain Barrier Penetrant Oral HER2 Tyrosine Kinase Inhibitor - businesswire.com","headline":"Zion Pharma Announces Global Agreement with Roche to Develop and Commercialize a Blood Brain Barrier Penetrant Oral HER2","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}